Y-mAbs Therapeutics, Inc. (YMAB)

Y-mAbs Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	67.23	78.64	105.76	181.56	114.63
Cash & Short-Term Investments	67.23	78.64	105.76	181.56	114.63
Cash Growth	-14.50%	-25.65%	-41.75%	58.39%	-44.66%
Receivables	19.69	22.45	12.53	7.71	-
Inventory	7.21	5.07	6.7	5.51	-
Other Current Assets	4.37	4.96	5.45	7.47	7.73
Total Current Assets	98.51	111.11	130.45	202.26	122.36
Property, Plant & Equipment	0.86	1.64	2.34	5.69	6.39
Other Intangible Assets	2.28	2.63	2.99	1.66	-
Other Long-Term Assets	18.26	12.49	5.68	3.17	3.29
Total Assets	119.9	127.87	141.46	212.78	132.05
Accounts Payable	6.66	6.06	14.18	13.55	9.37
Accrued Expenses	8.18	7.41	6.77	6.84	4.59
Current Portion of Leases	0.63	0.9	0.87	1.78	1.97
Other Current Liabilities	8.22	5.76	6.48	5.71	3.61
Total Current Liabilities	23.7	20.13	28.28	27.88	19.54
Long-Term Leases	0.19	0.52	0.9	1.85	2.01
Other Long-Term Liabilities	4.01	6.24	3.05	2.95	4.66
Total Liabilities	27.9	26.88	32.24	32.68	26.21
Common Stock	0	0	0	0	0
Additional Paid-In Capital	576.87	558	543.93	519.21	391.56
Retained Earnings	-487.14	-457.47	-436.04	-340.48	-285.2
Comprehensive Income & Other	2.26	0.45	1.33	1.37	-0.53
Shareholders' Equity	92	100.99	109.22	180.11	105.84
Total Liabilities & Equity	119.9	127.87	141.46	212.78	132.05
Total Debt	0.82	1.42	1.77	3.63	3.98
Net Cash (Debt)	66.41	77.22	104	177.93	110.66
Net Cash Growth	-13.99%	-25.75%	-41.55%	60.80%	-46.00%
Net Cash Per Share	1.50	1.77	2.38	4.12	2.76
Filing Date Shares Outstanding	45.22	43.78	43.68	43.71	43.53
Total Common Shares Outstanding	44.99	43.67	43.67	43.69	40.69
Working Capital	74.81	90.98	102.16	174.39	102.83
Book Value Per Share	2.05	2.31	2.50	4.12	2.60
Tangible Book Value	89.73	98.35	106.24	178.44	105.84
Tangible Book Value Per Share	1.99	2.25	2.43	4.08	2.60

Updated Mar 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q